Sign In
Buy RHHBY
$51.57
+2.51 (+5.12%)
At Close: Jun 04, 2026
Roche (RHHBY) Influenza Drug Gets FDA Nod for Children
12:03pm, Friday, 12'th Aug 2022
Roche (RHHBY) obtains FDA approval for expanded indication of influenza drug Xofluza.
Poseida Therapeutics (PSTX) Stock Rockets 79% on Roche Deal
12:21pm, Wednesday, 03'rd Aug 2022
Source: Shutterstock Poseida Therapeutics (NASDAQ: PSTX ) stock is soaring on Wednesday after the clinical-stage biotechnology company announced a deal with Roche (OTCMKTS: RHHBY ). The agreement with
How This Multibillion-Dollar Company Is Shaking Off the Competition
10:45am, Saturday, 30'th Jul 2022
The company has posted growth despite lower demand for several key products.
Roche to present scientific progress across Alzheimer's disease pharmaceutical and diagnostic portfolio at 2022 AAIC Annual Meeting
01:00am, Thursday, 28'th Jul 2022
Basel, 28 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that data from 41 abstracts across its portfolio of Alzheimer's disease pharmaceuticals and diagnostics will be presented at th
Roche Holding AG (RHHBY) CEO Severin Schwan on Q2 2022 Results - Earnings Call Transcript
02:52pm, Thursday, 21'st Jul 2022
Roche Holding AG (OTCQX:RHHBY) Q2 2022 Results Conference Call July 21, 2022 8:00 AM ET Company Participants Severin Schwan - CEO Bill Anderson - CEO, Roche Pharmaceuticals Thomas Schinecker - CEO, Ro
Roche backs 2022 outlook as profit climbs, boosted by diagnostics sales
02:35am, Thursday, 21'st Jul 2022
Roche Holding AG said Thursday that profit for the first half of the year increased as sales grew, mainly driven by the diagnostics division.
Roche diagnostics head to become group CEO
01:27am, Thursday, 21'st Jul 2022
Roche said the head of its diagnostics division, Thomas Schinecker, is to become group chief executive next year, replacing Severin Schwan, who will take the role of chairman of the board of directors
Roche core operating income up 9% in Q2
01:12am, Thursday, 21'st Jul 2022
Roche's second-quarter adjusted operating income rose a better-than-expected 9% on higher sales of diagnostic tests and pharmaceuticals.
What's Next For Roche Stock?
07:00am, Monday, 18'th Jul 2022
Swiss pharma giant Roche's stock (OTCMKTS: RHHBY) has seen an 8% rise in a month, outperforming the broader S&P500 index, which remained flat.
Roche (RHHBY) Announces 2-Year Data on Vabysmo for nAMD
03:18pm, Friday, 15'th Jul 2022
Roche's (RHHBY) new two-year data reinforce the long-term efficacy, safety and durability of Vabysmo in wet age-related mtacular degeneration.
Roche: The Undervalued Swiss Pharma Giant
04:54pm, Wednesday, 13'th Jul 2022
The street consensus anticipates 10.10% net profit and 6.77% free cash flow CAGR for Roche over the next 5 years. Ocrevus holds 20% of the global multiple sclerosis market share.
BAYRY vs. RHHBY: Which Stock Is the Better Value Option?
01:06pm, Tuesday, 12'th Jul 2022
BAYRY vs. RHHBY: Which Stock Is the Better Value Option?
Roche's (RHHBY) Lunsumio Application Gets Priority Review
02:45pm, Wednesday, 06'th Jul 2022
Roche's (RHHBY) BLA application seeking approval for the use of Lunsumio for relapsed or refractory follicular lymphoma has been granted priority review in the United States.
3rd-Quarter Clinical Trial Data Could Shake Up Pharma Stocks
11:43am, Tuesday, 05'th Jul 2022
Health care investors would be wise to keep tabs on the results of numerous drug trials scheduled to be revealed in the third quarter. Trial data can impact the stock price of a pharmaceutical company
Should You Buy, Sell, Or Hold Roche Stock At $42?
06:00am, Tuesday, 05'th Jul 2022
This marks an underperformance compared to some of its peers and the broader markets, with Johnson & Johnson stock rising 22%, Pfizer stock rising 41%, Merck stock up 5%, and the S&P 500 index rising
